Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05641246

Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine

Conditions: Hand and Foot Syndrome

Sex: Female

Ages: 18 Years – 80 Years

Phase: PHASE2

Enrollment: 66

Sponsor: German University in Cairo

Location: Egypt

Summary

The aim of the study is to evaluate the efficacy of using combination of Urea-based cream (CARBAMIDE®) and topical diclofenac (VOLTAREN®) Emulgel 1% for improving the incidence of Hand-foot syndrome in histologically proven breast cancer Egyptian patients receiving single agent chemotherapy Capecitabine (XELODA ®) and Its effect on improving patients' quality of life.

Eligibility Criteria

Inclusion Criteria:Adults aged 18 years and above.Females.Histologically proven breast cancer patients receiving Capecitabine (XELODA ®) chemotherapy.life expectancy greater than 18 weeks.Exclusion Criteria:Hypersensitivity to diclofenac, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS).History of Urticaria.History of acute rhinitisAsthmatic Patients.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05641246). StuddyBuddy aggregates publicly available trial information.